Bruce Booth Net Worth (2024) – wallmine.com (2024)

Last updated: 14 June 2024 at 6:05pm EST

The estimated Net Worth of Bruce Booth is at least $80.9 Milión dollars as of 12 June 2024. Bruce Booth owns over 26,940 units of Magenta Therapeutics Inc stock worth over $561,415 and over the last 10 years he sold MGTA stock worth over $80,126,267. In addition, he makes $201,447 as Independent Director at Magenta Therapeutics Inc.

Bruce Booth MGTA stock SEC Form 4 insiders trading

Bruce has made over 14 trades of the Magenta Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 26,940 units of MGTA stock worth $950,174 on 12 June 2024.

The largest trade he's ever made was buying 1,250,000 units of Magenta Therapeutics Inc stock on 29 June 2020 worth over $10,000,000. On average, Bruce trades about 87,247 units every 43 days since 2014. As of 12 June 2024 he still owns at least 802,022 units of Magenta Therapeutics Inc stock.

You can see the complete history of Bruce Booth stock trades at the bottom of the page.

BruceBooth biography

Dr. Bruce Booth D.Phil. serves as Independent Director of the Company. He is one of our founding investors and board members, has served as a member of our Board of Directors since February 2016. Dr. Booth joined Atlas Venture in 2005, and currently serves as partner. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm’s venture capital activities. Prior to Caxton, from 1999 to 2004, he was an associate principal at McKinsey & Company, a global strategic management consulting firm, where he advised clients on R&D productivity, corporate strategy and business development issues across the biopharmaceutical sector. Dr. Booth serves on the board of several privately held companies, as well as on the board of Unum Therapeutics Inc. and AVROBIO Inc. Dr. Booth previously served on the Board of miRagen Therapeutics, Inc. from 2007 to December 2018 and of Zafgen, Inc. from 2007 to June 2018. Dr. Booth also serves on UCB Pharma’s New Medicines Scientific Advisory Board, and participates on several other advisory boards for pharmaceutical companies and academic medical centers. As a British Marshall Scholar, Dr. Booth holds a D.Phil in molecular immunology from Oxford University’s Nuffield Department of Medicine and a B.S. in biochemistry, summa cum laude, from Pennsylvania State University. Booth’s extensive leadership, executive, managerial and business experience with life sciences companies, including experience in the formation, development and business strategy of multiple start-up companies in the life sciences sector qualifies him to serve on our Board of Directors.

What is the salary of Bruce Booth?

As the Independent Director of Magenta Therapeutics Inc, the total compensation of Bruce Booth at Magenta Therapeutics Inc is $201,447. There are 11 executives at Magenta Therapeutics Inc getting paid more, with ChristinaIsacson having the highest compensation of $2,277,560.

How old is Bruce Booth?

Bruce Booth is 45, he's been the Independent Director of Magenta Therapeutics Inc since 2016. There are 18 older and 2 younger executives at Magenta Therapeutics Inc. The oldest executive at Magenta Therapeutics Inc is DavidScadden, 67, who is the Independent Director.

What's Bruce Booth's mailing address?

Bruce's mailing address filed with the SEC is C/O KYMERA THERAPEUTICS, INC., 200 ARSENAL YARDS BLVD., SUITE 230, WATERTOWN, MA, 02472.

Insiders trading at Magenta Therapeutics Inc

Over the last 6 years, insiders at Magenta Therapeutics Inc have traded over $6,775,591 worth of Magenta Therapeutics Inc stock and bought 1,257,000 units worth $10,105,000. The most active insiders traders include Bruce Booth, Rock Ventures Iv, L.P.Third... a Jeffrey W. Albers.On average, Magenta Therapeutics Inc executives and independent directors trade stock every 46 days with the average trade being worth of $99,614. The most recent stock trade was executed by Rock Ventures Iv, L.P.Third... on 7 February 2023, trading 3,700,000 units of MGTA stock currently worth $3,071,000.

What does Magenta Therapeutics Inc do?

magenta therapeutics is a biotechnology company harnessing the power of stem cell science to revolutionize stem cell transplantation for patients with immune- and blood-based diseases. by creating a platform focused on key areas of transplant medicine, magenta therapeutics is pioneering an integrated, but modular approach to stem cell therapies that reboot the blood and immune systems to create patient benefit. founded by internationally recognized leaders in stem cell transplant medicine, magenta therapeutics was launched in 2016 by third rock ventures and atlas venture and is headquartered in cambridge, mass. for more information, please visit www.magentatx.com.

What does Magenta Therapeutics Inc's logo look like?

Magenta Therapeutics Inc executives and stock owners

Magenta Therapeutics Inc executives and other stock owners filed with the SEC include:

• ChristinaIsacson,
  Chief Business Officer
• JasonGardner,
  President, Chief Executive Officer, Co-Founder, Director
• JohnDavis,
  Chief Medical Officer, Head of Research and Development
• Dr. Jason Gardner Ph.D.,
  Co-Founder, CEO, Pres & Director
• Stephen F. Mahoney J.D., MBA,
  Chief Financial & Operating Officer and Treasurer
• AnneMcGeorge,
  Independent Director
• DavidScadden,
  Independent Director
• MichaelBonney,
  Independent Chairman of the Board
• AlexisBorisy,
  Independent Director
• JeffreyAlbers,
  Independent Director
• ThomasDaniel,
  Independent Director
• BruceBooth,
  Independent Director
• BlakeByers,
  Independent Director
• AmyRonneberg,
  Independent Director
• SteveMahoney,
  Chief Financial and Operating Officer
• ManishaPai,
  Vice President - Communications and Investor Relations
• ZoranZdraveski,
  Secretary and Chief Legal Officer
• LiMalmberg,
  Senior Vice President - Head of Manufacturing
• KristenStants,
  Chief People Officer
• CindyDriscoll,
  Vice President - Finance
• Dr. Jan Pinkas Ph.D.,
  Sr. VP & Head of Translational Sciences
• Catherine Monaghan,
  Head of Clinical Devel. Operations
• Kristen Stants,
  Chief People Officer
• Lyndsey Scull,
  Director of Corp. Communications
• Thomas W. Beetham,
  Chief Legal Officer
• Jim Haney,
  Sr. Director of Investor Relations
• Dr. Lisa M. Olson Ph.D.,
  Head of Research & Chief Scientific Officer
• David Wayne Nichols,
  Chief Technical Officer
• Lisa Olson,
  See Remarks
• Caren Deardorf,
  Chief Commercial Officer
• Venture Fund X, L.P.Atlas V...,
  
• Rock Ventures Iv, L.P.Third...,
  
• 2016 Gp, L.L.C.Gv 2016 Gp, ...,
  
• Jason Ryan,
  See Remarks
• Venture Fund X, L.P. Atlas,
  10% owner
• Stephen F. Mahoney,
  See Remarks
• Michael P. Cooke,
  Chief Scientific Officer
• Thomas W. Beetham,
  See Remarks
• Jeffrey Humphrey,
  Chief Medical Officer
• Alison Frances Lawton,
  Director
• David Wayne Nichols,
  Chief Technical Officer
• Michael Vasconcelles,
  Director